60 Degrees Pharmaceuticals Warrant
SXTPW
8 hedge funds and large institutions have $24.4K invested in 60 Degrees Pharmaceuticals Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
21% less capital invested
Capital invested by funds: $30.9K → $24.4K (-$6.5K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71 |
| 2 |
CS
Clear Street
New York
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$204 |
| 2 |
TSS
Two Sigma Securities
New York
|
-$134 |
| 3 |
Walleye Capital
New York
|
-$51 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6 |
SXTPW Hedge Fund Activity: Q1 2026 in Review
8 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in 60 Degrees Pharmaceuticals Warrant (SXTPW) for Q1 2026, worth a combined $24.4K — down 21% from $30.9K a quarter earlier.
Fund positioning in SXTPW was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $71. The largest seller was Citadel Advisors, cutting an estimated $204.
- 8 institutional investors held 60 Degrees Pharmaceuticals Warrant (SXTPW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $24.4K of 60 Degrees Pharmaceuticals Warrant stock for Q1 2026, down 21% quarter-over-quarter.
- 0 funds opened new 60 Degrees Pharmaceuticals Warrant positions in Q1 2026 and 0 closed out.
- The largest 60 Degrees Pharmaceuticals Warrant buyer in Q1 2026 was Susquehanna International Group, an estimated $71 added.
- The largest 60 Degrees Pharmaceuticals Warrant seller in Q1 2026 was Citadel Advisors, an estimated $204 sold.
Based on aggregated 13F filings for Q1 2026.